Share
Attention Deficit Hyperactivity Disorder (ADHD) and Cervical Cancer are covered on the National Health Fund’s (NHF) Card Programme.
The NHF in a statement today said this commenced yesterday and brings the number of conditions covered up to twenty-four.
It said coverage includes the Active Pharmaceutical Ingredient (API) Methylphenidate for individuals of all ages diagnosed with ADHD.
The subsidy for the Concerta 18 milligram tablet is $174.38.
As for cervical cancer, subsidies on eight APIs used in the treatment of the condition, including Bevacizumab, Carboplatin, Cisplatin, Gemcitabine, Filgrastim, Paclitaxel injections, as well as Dexamethasone and Metoclopramide tablets are available.
The available subsidies range from $2.64 for a dexamethasone-pms tablet 0.5 mg to $96,000 for Bevacizumab 400mg/16ml injection.
Further details can be found on the NHF’s website.
